共 50 条
- [31] Introducing 1,3-beta-d-glucan for screening and diagnosis of invasive fungal diseases in Australian high-risk haematology patients: is there a clinical benefit?INTERNAL MEDICINE JOURNAL, 2022, 52 (03) : 426 - 435Garnham, KatherineHalliday, Catriona L.Rai, Neela J.Jayawardena, MenukHasan, TasnimKok, JenNayyar, VineetGottlieb, David J.Gilroy, Nicole M.Chen, Sharon C. A.
- [32] Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery diseaseCIRCULATION, 2007, 115 (18) : 2398 - 2409Chan, Paul S.Nallamothu, Brahmajee K.Gurm, Hitinder S.Hayward, Rodney A.Vijan, Sandeep
- [33] Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell TransplantJOURNAL OF FUNGI, 2022, 8 (01)Dagher, HibaHachem, RayChaftari, Anne-MarieJiang, YingAli, ShahnoorDeeba, RitaShah, ShivanRaad, Issam
- [34] Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational studyJOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (09) : 2268 - 2273Auberger, JuttaLass-Floerl, CorneliaAigner, MariaClausen, JohannesGastl, GuentherNachbaur, David
- [35] Role of (1-3)-B-D-Glucan Test in the Diagnosis of Invasive Fungal Infections among High-Risk Patients in a Tertiary Care HospitalJOURNAL OF LABORATORY PHYSICIANS, 2022, 14 (03) : 306 - 311Sandhar, Tanureet KaurChhina, Deepinder KaurGupta, VeenuChaudhary, Jyoti
- [36] Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched AnalysisCLINICAL THERAPEUTICS, 2015, 37 (09) : 2019 - 2027Cho, Sung-YeonLee, Dong-GunChoi, Jae-KiLee, Hyo-JinKim, Si-HyunPark, Sun-HeeChoi, Su-MiChoi, Jung-HyunYoo, Jin-HongKim, Yoo-JinKim, Hee-JeMin, Woo-SungBack, HeejungKang, SukhyunLee, Eui-Kyung
- [37] Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospitalJOURNAL OF MEDICAL ECONOMICS, 2016, 19 (01) : 77 - 83Chan, Thomas S. Y.Marcella, Stephen W.Gill, HarinderHwang, Yu-YanKwong, Yok-Lam
- [38] Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia:: interim analysis of a prospective studyMYCOSES, 2001, 44 (11-12) : 455 - 463Uhlenbrock, SZimmermann, MFegeler, WJürgens, HRitter, J
- [39] COST ANALYSIS OF VORICONAZOLE VERSUS CASPOFUNGIN FOR PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS AMONG HIGH-RISK HEMATOLOGIC CANCER PATIENTS IN CHINAVALUE IN HEALTH, 2015, 18 (03) : A295 - A295Gao, X.Xue, M.Stephens, J.Chen, Y.Haider, S.Charbonneau, C.
- [40] Clinical risk score for predicting invasive fungal disease after allogeneic hematopoietic stem cell transplantation: Analysis of the China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) studyTRANSPLANT INFECTIOUS DISEASE, 2021,Sun, YuqianHu, JiongHuang, HeChen, JingLi, JianyongMa, JunLi, JuanLiang, YingminWang, JianminLi, YanYu, KangHu, JiandaJin, JieWang, ChunWu, DepeiXiao, YangHuang, Xiaojun